Selective antagonism by naltrindole of the antinociceptive effects of the delta opioid agonist cyclic[D-penicillamine2-D- penicillamine5]enkephalin in the rat

EJ Drower, A Stapelfeld, MF Rafferty, BR de Costa, KC Rice and DL Hammond

Department of Central Nervous System Research, G.D. Searle & Co., Skokie, Illinois.

Spinal delta opioid receptors have been proposed to mediate antinociception in the rat on the basis of 1) the efficacy of a small number of agonists; 2) the lack of effect of mu-selective antagonists; and 3) the lack of cross-tolerance with mu-selective agonists. However, direct evidence to support or refute this postulate has not been obtained in the rat due to a lack of suitable delta-selective antagonists. The present study characterized the ability of Naltrindole (NTI, 17-cyclopropylmethyl-6,7-dehydro-4,5 alpha-epoxy-3,14-dihydroxy- 6,7-2',3'-indolomorphinan), a recently discovered delta-selective antagonist, to antagonize the antinocieption produced by intrathecal (i.t.) administration of the prototypic delta-selective agonist cyclic[D-penicillamine2-D-penicillamine5]enkephalin (DPDPE) or the mu- selective agonists morphine and [D-Ala2,MePhe4,Gly-ol5] enkephalin (DAMGO) in the rat. Intrathecal coadministration of NTI with DPDPE significantly antagonized the increase in tail-flick latency (TFL) and hot-plate latency (HPL) produced by DPDPE. In the absence of NTI, the ED50 values and 95% CL of DPDPE in the tail-flick and hot-plate tests were 2.8 (1.1-4.7) and 19.5 (13.3-33.7) micrograms, respectively. In the presence of 10 micrograms of NTI, the ED50 value of DPDPE in the tail-flick test was unchanged and was increased by 2-fold in the hot- plate test to 35.9 (26.2-60.1) micrograms. In the presence of 30 micrograms of NTI, the ED50 value of DPDPE in the tail-flick test was increased by 5-fold to 14.5 (8.5-24.9) micrograms and its antinociceptive effect in the hot-plate test was antagonized completely.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 259, Issue 2, pp. 725-731, 11/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. I. Svensson, Y. Rew, S. Malkmus, P. W. Schiller, J. P. Taulane, M. Goodman, and T. L. Yaksh Systemic and Spinal Analgesic Activity of a {delta}-Opioid-Selective Lanthionine Enkephalin Analog J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 827 - 832. [Abstract] [Full Text] [PDF]

				K. Horais, V. Hruby, S. Rossi, D. Cizkova, C. Meschter, R. Dorr, and T. L. Yaksh Effects of Chronic Intrathecal Infusion of a {partial} Opioid Agonist in Dogs Toxicol. Sci., February 1, 2003; 71(2): 263 - 275. [Abstract] [Full Text] [PDF]

				S. F. Sezen, V. A. Kenigs, and D. R. Kapusta Renal Excretory Responses Produced by the Delta Opioid Agonist, BW373U86, in Conscious Rats J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 238 - 245. [Abstract] [Full Text]

				M. J. Hepburn, P. J. Little, J. Gingras, and C. M. Kuhn J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1350 - 1356. [Abstract] [Full Text]